![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:4351B Cambridge Antibody Tech Group PLC 2 April 2001 01/CAT/05 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 David Chiswell, CEO John Aston, Finance Director Rowena Gardner, Head of Corporate Communications HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Adam Michael David Speechly BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext 17 (media) Brandon Lewis, ext.15 (investors) CAT COMMENTS ON COURT DECISION Melbourn, UK. The jury in the District Court of Washington DC was unable to reach a decision on all but one of the issues before it in the action brought by MorphoSys seeking a declaration that Cambridge Antibody Technology's US "Griffiths" patent ( US 5,885,793 co owned by the MRC) is invalid and/or that MorphoSys does not infringe the patent. Cambridge Antibody Technology (LSE:CAT) subsequently counterclaimed in the action that MorphoSys did infringe the patent. The one issue the jury did agree on was, in favour of CAT, that CAT was entitled to the priority dates of its British applications. Several post trial motions are being filed with the court and the parties are awaiting the Court's decision. If the court does not issue a dispositive ruling on the question of validity then the case will be retried at a later date to be arranged. Notes to Editors: Cambridge Antibody Technology (LSE: CAT) CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 220 people. CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. A secondary offering in March 2000 raised #93m. CAT has a world-leading platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT works in partnership with other companies at all stages of the drug discovery and development process. CAT's collaborations, past and present, include: AstraZeneca, BASF Pharma, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst and Zyomyx. Background to CAT's patents CAT's patent portfolio includes about 30 families of patents, covering both technologies and products. CAT's core phage display technology is covered by three main families of patents. CAT and the MRC were awarded the US 'Griffiths' patent in March 1999 (the patent is co-owned). The Griffiths patent relates to methods of isolating specific antibodies to human self-antigens from phage display libraries and to antibodies produced by these methods. In April 1999 MorphoSys filed a 'declaratory judgement action' in the US District Court of Washington DC, asking the Court to declare that the CAT's patent is invalid, and/or declare that it does not infringe the patent. CAT counter-claimed against MorphoSys for infringement. Infringement litigation is pending in the same Court in respect of CAT's US "McCafferty" patent, US 5,969,108. A trial date has been set for April 2002.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions